ASH 2025 | Safety & efficacy of INCA033989, a first-in-class mutant CALR-specific mAb, in patients with ET & MF

This ASH was really notable for the coverage of the really first sort of comprehensive results with 989 INCA, which is the Incyte monoclonal FC silent antibody targeting calreticulin as it’s expressed with MPL on the surface of cells. We saw at EHA 2025 some results with patients with ET showing a very prompt reduction in platelet count and other benefits for patients. And we will present that at ASH with extended data for ET patients. What was totally new at ASH were two aspects. First, the data presented by John Mascarenhas in myelofibrosis patients. So monotherapy for the majority of patients, but also small cohort of patients with combination. What we saw was improvements in spleen, symptoms, improvements in hemoglobin, and super well-tolerated. So we invented a fun new term, super well-tolerated. We normally say generally well-tolerated. What we saw was profound changes in the bone marrow, significant reductions in mutant-expressing cells, and correlations between some of these and improvements. So, for example, we saw changes in the number of non-mutated red cell precursors as well as improvements in hemoglobin. So, this is really profound for the field because we saw these changes in the bone marrow architecture as well as benefits for patients. So it’s super exciting as well that the agent is really well tolerated. So I would urge listeners to either come along to the post-ASH and hear this discussed in more detail or tune in and watch the presentation online.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.